Navigation Links
SemBioSys announces 2007 financial and operational results
Date:3/17/2008

- Canadian Biotechnology Company advances pharmaceutical programs while

executing on non-pharmaceutical opportunities -

TSX symbol: SBS

CALGARY, March 17 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced its operational and financial results for the twelve-month period ended December 31, 2007.

"We made progress on multiple product candidates during 2007 that was essential to setting the stage for significant value creating milestones in 2008. We believe that each of our candidates individually represent an exciting and material opportunity to the growth of our company. The basis for this growth is the flexibility of our proprietary oilbody-oleosin technology which allows us to target multiple markets that require high volume, cost-effective pharmaceutical and non-pharmaceutical products," said Andrew Baum, President and CEO of SemBioSys Genetics Inc. "Establishing Botaneco as a separate operating company with genuine value creating potential and achieving commercially viable levels of Apo AI accumulation were some of the key highlights of the year for us. Additionally, we have made significant progress on the insulin program including the necessary preclinical work to submit an IND in order to begin the Phase I/II clinical trial in the second half of 2008. While we have adjusted the expected start date of the insulin clinical trial, we believe the insulin program represents just one of the important upcoming milestones for SemBioSys in 2008. We also expect in vivo functional and efficacy results from Apo AI(Milano), which has the potential to attract partnership opportunities as well as further growth and business development opportunities from Botaneco. Our recent achievements have also begun to attract interest from new potential partners that believe the capab
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
2. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
3. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys announces 2007 third quarter results
6. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
7. SemBioSys updates Apo AI development program
8. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
9. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
10. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
11. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 ... patient registry platform, announced that three PatientCrossroads-based ... dystrophies; the Phelan-McDermid Syndrome International Registry; and ... Syndrome—have been awarded contracts by the Patient-Centered ... the creation of a new health data ...
(Date:7/13/2014)... discovery 30 years ago of soccer-ball-shaped carbon molecules called ... Now, there appears to be a new ball on ... and Tsinghua University in China have shown that a ... cage similar to a carbon buckyball. It,s the first ... matter of speculationdoes indeed exist. , "This is the ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Silver Industry” is a professional and in-depth study on ... Global and China. , The report provides a basic ... chain structure. Global market analysis and Chinese domestic market ... trends and competitive landscape of the market. A comparison ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
Breaking Biology Technology:PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3
... of assay of cell-mediated ... immunity, ... data on the monitoring of cell-mediated immunity (CMI) in adult patients,undergoing heart ... demonstrated that ImmuKnow(R) values,appear to closely reflect the immune function of the ...
... REHOVOT, Israel and JERSEY CITY, New Jersey, April ... leader in,the development of microRNA-based diagnostics and therapeutics, ... upcoming annual AACR,conference in San Diego. The posters ... and how they may be applied to develop,objective ...
... Zentaris Inc.,(Nasdaq: AEZS TSX: AEZ;), a global biopharmaceutical ... that David J. Mazzo, Ph.D.,has resigned as President ... the,Board of Directors of AEterna Zentaris, effective immediately. ... of AEterna Zentaris, has been,appointed as the interim ...
Cached Biology Technology:Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 2Immune Function in Adult Heart Transplant Patients Reflects Risk for Organ Rejection and Infection 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 2Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 3Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 4Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference 5AEterna Zentaris Announces Changes to its Management Team 2
(Date:7/10/2014)... SPRINGS, Colo. , June 27, 2014 /PRNewswire/ ... that the National Institute of Standards and Technology ... 10 of its academic research and forensic science ... (FSSB).  The Board is an element of the ... AAFS members are among the first appointments made ...
(Date:7/10/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... June 26, 2014 that its Board of Directors had ... or approximately $40 million in total.  The Board established ... payment date of July 24, 2014.  The Company was ... ex-dividend date for this special cash dividend.  An ex-dividend ...
(Date:7/10/2014)... July 2, 2014  Unisys Corporation,s (NYSE: UIS ... Nederland N.V., today announced that it has been selected by ... manage a new Basic Provision Biometrics solution for penitentiaries across ... won the contract with a solution based on its open ... term of the contract is up to seven years, with ...
Breaking Biology News(10 mins):Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... Wallace, PhD, a pioneering genetics researcher who founded the ... 2012 Genetics Prize of The Gruber Foundation. Wallace is ... groundbreaking achievements in helping science understand the role of ... and as markers for human evolution., He will receive ...
... , ,Oligonucleotide technologies, such as siRNA, tap into ... efficiently regulate gene expression. As such, they have ... therapeutic options for disease targets previously considered un-druggable ... despite the promise, clinical development has been hindered ...
... a half-dozen palladium- and iron-based catalysts for cleaning up the ... TCE far faster than iron -- up to a billion ... in a new study in the August issue of the ... trichloroethene, is a widely used chemical degreaser and solvent that,s ...
Cached Biology News:$500,000 Gruber Foundation Genetics Prize goes to Philadelphia scientist 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 2Oligonucleotide Delivery: Biology, Engineering and Development Conference 3Palladium-gold nanoparticles clean TCE a billion times faster than iron filings 2
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide ... UNDER INERT GAS. A potent inhibitor of ... (K i = 1.7 μM). ... EtOH or DMSO. Unstable in solution, reconstitute ...
... early protein. Can detect ... exhibiting an intranuclear inclusion staining ... 6-24 hours. These antibodies ... staining. No other nuclear ...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Goat polyclonal to DRAK2...
Biology Products: